Publications by authors named "Georgia Spear"
Breast cancer does not wait until a woman reaches her 50's to strike. One in six cases occurs in women between the ages of 40 and 49 and breast cancer is the most prevalent cancer and the leading cause of cancer-related deaths among women under 50 in the United States (10% of breast cancer deaths), emphasizing the urgency of early detection (American Society. 2024).
View Article and Find Full Text PDFImproving Lesion Location Reproducibility in Handheld Breast Ultrasound.
Diagnostics (Basel)
July 2024
Article Synopsis
- - The study examined how differences between operators in handheld ultrasound (HHUS) affect the consistency of locating breast lesions, which can impact patient care.
- - Researchers analyzed the positioning of small breast masses in 28 patients using both manual and computer-assisted methods, finding that the computer-assisted approach led to more accurate localization and faster annotation times.
- - The study concluded that using a computer-assisted scanning device improves the reproducibility of breast mass locations and enhances overall efficiency during HHUS procedures.
Objective: We review ultrasound (US) options for supplemental breast cancer screening of average risk women with dense breasts.
Conclusion: Performance data of physician-performed handheld US (HHUS), technologist-performed HHUS, and automated breast ultrasound (AUS) indicate that all are appropriate for adjunctive screening. Volumetric 3D acquisitions, reduced operator dependence, protocol standardization, reliable comparison with previous studies, independence of performance and interpretation, and whole breast depiction on coronal view may favor selection of AUS.
Background: It is unclear if breast magnetic resonance imaging (MRI) is more accurate than mammography (MGM) and ultrasound (U/S) in aggregate for patients with invasive cancer.
Methods: We compared concordance of combined tumor size and tumor foci between MRI and MGM and U/S combined to pathological tumor size and foci as the gold standard from 2009 to 2015. Tumor size was nonconcordant if it differed from the pathologic size by ≥33% and tumor foci was nonconcordant if >1 foci were seen.